| Etoricoxib vs placebo | Naproxen vs placebo | Etoricoxib vs naproxen |
---|---|---|---|
Primary endpoints | Â | Â | Â |
Patient global assessment of disease activity (100 mmVAS) ‡ | -9.93* (-12.96, | -10.0* (-13.7, | 0.09 (-3.61, 3.79) |
 | -6.90) | -6.32) |  |
Investigator global assessment of disease activity (0–4 scale) ‡ | -0.43* (-0.55, | -0.51* (-0.66, | 0.08 (-0.08, 0.24) |
 | -0.30) | -0.35) |  |
Tender joint count (total 68 joints) ‡ | -3.42* (-4.89, | -3.16* (-4.96, | -0.26 (-2.05, 1.54) |
 | -1.94) | -1.36) |  |
Swollen joint count (total 66 joints) ‡ | -1.43†(-2.42, | -1.39†(-2.60, | -0.03 (-1.24, 1.17) |
 | -0.44) | -0.19) |  |
Secondary endpoints | Â | Â | Â |
Patient global assessment of pain (100 mm VAS) ‡ | -9.62* (-12.73, | -10.46* (-14.25, | 0.84 (-2.96, 4.63) |
 | -6.51) | -6.66) |  |
Health Assessment Questionnaire disability (0–3 scale) ‡ | -0.20* (-0.28, | -0.29* (-0.38, | 0.08 (0.00, 0.17) |
 | -0.13) | -0.20) |  |
Serum C-reactive protein (ratio between treatments) | 1.11†(1.00, 1.23) | 0.99 (0.87, 1.13) | 1.12 (0.99, 1.27) |
ACR20 responder criteria (%) | 17.83* (10.55, 25.12) | 16.68* (7.80, 25.57) | 1.15 (-7.74, 10.03) |
Discontinuation due to lack of efficacy (%) | -12.75* (-18.42, | -14.71* (-21.06, | 1.97 (-3.67, 7.61) |
 | -7.07) | -8.37) |  |